Icon

Caplyta - (10.5 and 21 mg ; Capsule, Oral)

Lumateperone Tosylate Intra-Cellular
10.5 and 21 mg ; Capsule, Oral
Less Than $1000 mn
More Than 5
More Than 5
Less Than 5
None
None None
CAPLYTA is an atypical antipsychotic indicated for the treatment of: • Schizophrenia in adults. • Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
Yes
Caplyta Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15
***** *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, ****
** *****'* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
****** **** ** *** **, **** *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ********* *** **, **** ******* **** *** ****** *** ****
** *****'* *** \ ********* *** **, **** ******* **** *** ****** *** ****
****** *** \ ********* *** **, **** ******* **** *** ****** *** ****
  1. *** **, **** : * **** ** ** ***** *** ***** *** *** ****.
  2. *** **, **** : ***** ******** *****-******** ***** *** **** ** ******.
  3. *** **, **** : ****** ******** *****-******** ***** *** **** ** ******.
  4. *** **, **** : *****, ** ****** *** *** ******** *****-******** ***** *** **** ** ******.
  5. *** **, **** : ****** ******** *****-******** ***** *** **** ** ******.
  6. *** **, **** : *****-******** ***** * **** ******* ***** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '*** *** '***.
  7. *** **, **** : *****-******** ***** * **** ******* ** ****** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** *** '***.
  8. *** **, **** : *****-******** ***** * **** ******* ****** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, *** '***.
  9. *** **, **** : *****-******** ***** * **** ******* *** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, *** '***.
  10. *** **, **** : *****-******** ***** * **** ******* ****** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** *** '***.
  11. *** **, **** : *****-******** ***** * **** ******* ***** **** ************ ** ****** ** '***, '***, '***, '*** *** '***.

Caplyta - (42 mg ; Capsule, Oral)

Lumateperone Tosylate Intra-Cellular
42 mg ; Capsule, Oral
Less Than $1000 mn
More Than 5
More Than 5
Less Than 5
None
None None
CAPLYTA is an atypical antipsychotic indicated for the treatment of: • Schizophrenia in adults. • Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
Yes
Caplyta Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16
********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, ****
***** *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, ****
** *****'* *** ********* **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
********* *** \ ********* *** **, **** ******* **** *** ****** *** ****
***** *** \ ********* *** **, **** ******* **** *** ****** *** ****
** *****'* *** \ ********* *** **, **** ******* **** *** ****** *** ****
  1. *** **, **** : * **** ** ** ***** *** ***** *** ***** ****.
  2. *** **, **** : ********* *** ***** ******** *****-******** ***** *** **** ** ******.
  3. *** **, **** : *****-******** ***** * **** ******* ********* **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '*** *** '***.
  4. *** **, **** : ****** ******** *****-******** ***** *** **** ** ******.
  5. *** **, **** : *****, ** ****** *** *** ******** *****-******** ***** *** **** ** ******.
  6. *** **, **** : ****** ******** *****-******** ***** *** **** ** ******.
  7. *** **, **** : *****-******** ***** * **** ******* ***** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '*** *** '***.
  8. *** **, **** : *****-******** ***** * **** ******* ** ****** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** *** '***.
  9. *** **, **** : *****-******** ***** * **** ******* ****** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, *** '***.
  10. *** **, **** : *****-******** ***** * **** ******* *** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, *** '***.
  11. *** **, **** : *****-******** ***** * **** ******* ****** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** *** '***.
  12. *** **, **** : *****-******** ***** * **** ******* ***** **** ************ ** ****** ** '***, '***, '***, '*** *** '***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.